Head and neck squamous cell carcinomas (HNSCC) is a common cancer in humans long known to be caused by tobacco and alcohol use, but now an increasing percentage of HNSCC is recognized to be caused by the same human papillomaviruses (HPVs) that cause cervical and other anogenital cancers. HPV-positive HNSCCs differ remarkably from HPV-negative HNSCCs in their clinical response and molecular properties. From studies in mice, we know that E7 is the dominant HPV oncoprotein in head and neck cancer. E7 is best known for its ability to inactivate pRb, the product of the retinoblastoma tumor susceptibility gene. However loss of pRb function does not fully account for E7's potency in causing head and neck cancer. In this study, we characterized the cancer susceptibility of mice deficient in the expression of pRb and either of two related "pocket" proteins, p107 and p130, that are also inactivated by E7. pRb/p107 deficient mice developed head and neck cancer as frequently as do HPV16 E7 transgenic mice. The head and neck epithelia of the pRb/p107 deficient mice also displayed the same acute phenotypes and biomarker readouts as observed in the epithelia of E7 transgenic mice. Mice deficient for pRb and p130 in their head and neck epithelia showed intermediate acute and tumor phenotypes. We conclude that pRb and p107 act together to efficiently suppress head and neck cancer, and are therefore highly relevant targets of HPV16 E7 in its contribution to HPV-positive HNSCC.
Introduction
Head and neck squamous cell carcinomas (HNSCC) is the sixth most common human cancer. Tobacco use and alcohol consumption have long been known to contribute to increased risk of HNSCC. In the past decade, there has been a growing appreciation that Human Papillomaviruses (HPVs) cause approximately 20% of all HNSCCs and up to 60% of HNSCC arising in the oropharynx including the tonsils (1) (2) . In the US and Europe, the incidence of HPV-positive (HPV+)HNSCC is increasing while incidence of HPV-negative (HPV-)HNSCC is declining, the latter correlating with reduced use of tobacco in these countries (3) . HPV type 16, a high-risk human papillomavirus (HR-HPVs), is associated with the vast majority of HPV+HNSCC (1, 4) .
HPV+HNSCC differ from HPV-HNSCC at multiple levels including patient demographics, tumor histopathology, mutation and gene expression profiles, and clinical prognosis. Incidence of HPV+HNSCC is higher in young individuals and less tightly linked with alcohol consumption and smoking (5) (6) . Patients with HPV+HNSCC have higher survival rates compared to those with HPV-HNSCC when provided standard of care treatment, despite the fact that HPV+HNSCC tend to be more poorly differentiated cancers. On a molecular basis, HPV+HNSCC differ from HPV-HNSCC remarkably in their mutational profiles, with greatly reduced frequencies of mutations in cellular genes, and the absence of mutations in genes such as p53, which is commonly mutated in HPV-HNSCC (6) . This difference holds true even for HPV+HNSCC arising in smokers, which supports the premise that HPV is the major driver of the cancer phenotype in HNSCCs positive for this tumor virus. Consistent with this premise, knock down of expression of HPV oncogenes in HPV+HNSCC cell lines leads to cell death (7) .
HPV+HNSCC also have gene expression profiles very distinct from HPV-HNSCC and more similar to that of HPV-positive cervical cancer (8) . These molecular differences have been largely attributed to the activities of the HPV-encoded oncogenes.
HR-HPVs such as HPV16 encode for three oncogenes; E5, E6, and E7. Of these, E6 and E7 are commonly found to be expressed in HPV+ HNSCC (9) , much like in cervical cancer (10) . HR-HPV E6 binds to and induces to the degradation of p53, while HR-HPV E7 binds to and induces degradation of pRb and its related pocket protein family members, p107 and p130 (11) (12) . Previously, we reported that HPV-16 E7 is the dominant viral oncogene in HPV-associated HNSCC, based on studies in which HPV16 transgenic mice were treated with the chemical carcinogen, 4-nitroquinoline 1-oxide (4-NQO) (13) (14) . We have also learned that pRb inactivation by E7 is not sufficient to account for the oncogenic potential of E7 in HNSCC: conditional deletion of pRb in head and neck epithelia only partially recapitulated the acute and tumorigenic phenotypes bestowed on mice by E7 (13) . These results led us ask what other cellular proteins targeted by E7 contribute to HNSCC.
Here, we report that the combinational loss of pRb along with either p107 or p130 with pRb increased greatly the susceptibility of mice to head and neck tumors over that seen in mice deficient for any one pocket protein. Mice deficient for pRb and p107 in their epithelia had head and neck cancer incidence and severity of disease indistinguishable from that seen in E7 transgenic mice. The oncogenic phenotype in mice deficient for both p107 and pRb was more severe than in mice deficient for both p130 and pRb. Biomarker expression profiles in p107/pRb deficient mice approximated that in 5 E7 transgenic mice. Compensatory increases in the expression of the remaining pocket protein was observed in mice deficient for two pocket proteins, which in the case of the p130/pRb deficient mice might account for the reduced overall tumor susceptibility. The high degree of susceptibility of p107/pRb deficient mice to head and neck cancer is consistent with the hypothesis that E7 inactivation of these two pocket proteins primarily drives E7 oncogenic properties in HPV+HNSCC. 
Materials and Methods
Mice: K14E7 mice have been described previously (13) (14) Control nontransgenic and K14E7 transgenic mice were generated on the same mixed genetic background for al comparison made in this study.
For the irradiation studies, mice were exposed to 0 or 12 Gy ionizing radiation from a 137Cs source 24 hours before mice were injected IP with BrdU (10µl per g body weight of 12.5mg/ml solution). These mice were then sacrificed 1 hour later and tissues harvested. All mice were bred and maintained in the American Association for 
4-nitroquinoline-N-oxide (4-NQO)-induced head and neck carcinogenesis
study and histological analysis. For the head and neck carcinogenesis studies, we started to supply 4-nitroquinoline-N-oxide dissolved water 7 days following completion of treatment with tamoxifen. The treatment and guidelines for histologic analysis were previously described (13) . To evaluate the tumor in head and neck, the tongue and esophagus were fixed in 4% (vol/vol) paraformaldehyde solution, embedded in paraffin, and thin sectioned (5μm). Approximately 20 sections were collected at 100 μm intervals for H&E staining and examined for the presence of either papillomas or carcinomas.
Based upon detailed assessment of the grade of disease in each section, a diagnosis of the worst grade of disease for each mouse was assigned. Initial histological analysis to identify location of lesions was made by M.K.S. Final diagnoses were made by H.C.P., a mouse pathologist, who was blinded to the mouse genotype. Quantification of DNA synthesis were performed as previously described (18) (19) (20) .
Immunohistochemistry. All of immunohistochemistry were performed as as previously described (18) (19) (20) . Briefly, the primary antibodies were used in different condition as follows: anti-pRb (1:25, in 5% horse serum, BD Biosciences), anti-p107
(1:125 in 5% non-fat milk/5% horse serum, Santa Cruz Biotechnology), anti-p130 (1:100 8 in 5% non-fat milk/5% horse serum, BD Biosciences), anti-BrdUrd (1:50 in 5% horse serum, Calbiochem)., anti-Mcm7 (1:200 in 5% non-fat milk/5% horse serum, LabVision Neomarkers), anti-p16 (1:50 in 5% non-fat milk/5% horse serum, Santa Cruz Biotechnology), anti-E2F1 (1:150 in 5% non-fat milk/5% horse serum, Abcam), and anti-EZH2 (1:50 in 5% non-fat milk/5% horse serum, BD Biosciences) were used for immunohistochemistry.
Statistical analysis. A two-sided Fisher's exact test was used to determine the significance of differences in the incidence of overt tumor between each mice group. To determine the significance of differences in the severity of disease and DNA synthesis level between each mouse group, a two-sided Wilcoxon rank sum test was used. 
Results
Conditional inactivation of both Rb and p107, or Rb and p130 in head and neck epithelia. We have previously shown that pRb inactivation by E7 is not sufficient to account for HPV-16 E7-mediated oncogenic potential in head and neck cancer (13) .
HPV-16 E7 has been reported to bind and degrade other pocket protein family members, p107 and p130 (21) . To determine if combinatorial loss of two pocket proteins by E7 contributes to increased susceptibility to HNSCC in mice, we generated mice that were inactivated for both pRb and p107, or pRb and p130 in their stratified squamous epithelia.
To generate mice inactivated for both pRb and p107 in this tissue, K14CreERtm 
Suprabasal DNA synthesis in head and neck epithelia deficient in pocket proteins
A hallmark of E7 is its ability to induce DNA synthesis in the normally quiescent suprabasal compartment of the stratified epithelia (24-26) including head and neck epithelia (13) . Loss of pRb in head and neck epithelia recapitulated some but not all E7-mediated effects on DNA synthesis (13) . To determine if combined loss of pRb and p107, or pRb and p130 in head and neck epithelia was able to more completely account for this acute phenotype of E7, we analyzed the proliferative index in the lingual and esophageal epithelium by quantifying the frequency of bromo-deoxyuridine (Fig. 2B) , and is consistent with our prior study (13) . Similarly, with tamoxifen-treated K14CreERtmRb mice compared to mice inactivated for one of these pocket proteins, but this induction again was less than that caused by E7 expression in the same epithelia (Fig. 2B ). These observations demonstrate that combinational loss of pRb and either p107 or p130 is not sufficient to account fully for E7's ability to induce suprabasal DNA synthesis in head and neck epithelia.
Inhibition of DNA damage response in irradiated head and neck epithelia deficient for pRb and p107, or pRb and p130. HR-HPV E7 is able to disrupt DNA damage responses including those that arise in epithelia of mice exposed to ionizing radiation (27) (28) (29) . In mouse epithelia, this DNA damage response is reflected in the reduction in frequency cells supporting DNA synthesis 24 hours following exposure to radiation. pRb inactivation alone was necessary and sufficient to inhibit DNA damage response in the epidermis of mouse skin, but not in the murine cervix (19, (30) (31) . To determine the influence of pocket proteins on DNA-damage response in head and neck epithelia, we quantified the frequency of cells undergoing DNA synthesis in the lingual and esophageal epithelia of mice deficient for pocket proteins that were exposed to 12 Gy ionizing radiation, a dose we had determined is sufficient to cause an arrest in DNA synthesis in these tissues in syngeneic (pocket protein sufficient) mice. DNA synthesis was scored by monitoring incorporation of BrdUrd into newly synthesized DNA in basal cells by immunohistochemistry (mice injected with BrdUrd one hour prior to sacrifice). For comparison, we monitored DNA damage responses in the head and neck epithelia of K14E7 transgenic mice. Radiation-induced arrest of DNA synthesis was observed in nontransgenic, pocket protein sufficient mice but abrogated in K14E7 mice (Fig. 2C&D) .
In K14CreRb f/f , no effect of pRb inactivation alone was seen in blocking DNA-damage induced arrest of DNA synthesis (Fig. 2D) . Similarly inactivation of either p107 (Fig. 2C) or p130 ( As an aside, we saw a reduction in baseline levels of DNA synthesis (i.e. in the absence of radiation) in the basal cells deficient for either p107 (Fig 2C) or p130 (Fig   2D) alone compared to nontransgenic (p107 and p130 sufficient) mice, but this reduction was not seen in tissues deficient for pRb alone (Fig 2D) . This reduction in DNA synthesis in the basal cells of p107 or p130 deficient tissue was not due to an increase in pRb levels (see Fig. 1 ). , and K14E7. Consistent with our prior studies (13) , K14E7 mice developed a high incidence of overt tumors at greater than 90% while the nontransgenic mice had less than 10% incidence of overt tumors (Fig. 3A, 3B ). with that observed in the nontransgenic mice ( Fig. 3B; p<0 .05), but significantly lower incidence than that developed observed in the K14E7 mice (Fig. 3B, p<0.05) . Rb f/f p130 -/-mice had no significant increase in the incidence of overt tumors compared with that observed in the nontransgenic mice (Fig 3B; p=0.26 (Fig 3B; p<0.05), but was still significantly lower than the incidence observed in K14E7 mice (Fig. 3B, p<0 .05). To do so, the tissues from a subset of mice of each genotype were randomly selected, embedded in paraffin, sectioned, stained with H&E and subjected to detailed histopathological analysis. Similar to what we have previously observed (13) Table. 2) and they also developed more severe disease overall compared to nontransgenic mice (Tables 1   and 2 ). Mice inactivated for either pRb or p107 did not develop any invasive cancers (Tables 1 & 2 likely due to the inactivation of pocket proteins by E7 (19) . It is also likely that p16 is highly expressed because of the dysregulation of p16-pRb pathway in E7-expressing cells (5-6). To determine if combined loss of pRb and p107, or pRb and p130, lead to dysregulation of these two biomarkers of human HNSCC, we performed MCM7 and p16 immunohistochemical staining on lingual epithelium as well as tumors arising in these mice (Fig. 4) . , Similar results were obtained data on esophageal epithelium and tumors (data not shown).
Incidence of overt tumors in
As expected (13), the expression of MCM7 was highly up-regulated in both lingual epithelium and tumors arising in K14E7 mice (Fig. 4, left panel) . In nontransgenic mice, MCM7 was only expressed in the basal cell layer head and neck epithelia and poorly expressed in the tumors. MCM7 staining in head and neck epithelium of both When we performed p16-specific immunohistochemistry of head and neck tissues (Fig. 4, right Author Manuscript Published OnlineFirst on January 11, 2012; DOI: 10.1158/0008-5472. CAN-11-2833 mice. In E7 transgenic and to varying degrees in the mice inactivated for pocket proteins, we detected a higher intensity of staining for p16, often with increased nuclear signal. This was most pronounced with the mice inactivated for both p107 and pRb.
These findings (see Fig. S1 for quantification of p16 positivity for each genotype) indicate that each pocket protein can modulate the expression of p16, but loss of Rb and p107 has the most dramatic effect on inducing expression of this Cdk inhibitor.
Together with the MCM7 staining results, we can conclude that the inactivation of pocket proteins is largely responsible for the unique pattern of staining for MCM7 and p16 in HPV-associated human cancers. To look further at the dysregulation of the p16-RB pathway in mice disrupted in expression of the pocket proteins, we monitored levels of expression of E2F1, itself an E2F responsive gene (35) (36) (Supplementary Fig. S2 ). In nontransgenic mice E2F1 was detected at low levels in the basal compartment of head and neck epithelia whereas it was more strongly detected throughout the full thickness of the epithelium in K14E7 mice. Again, the inactivation of both p107 and pRb most closely reproduced the strong E2F1 staining pattern throughout the epithelium that was observed in E7 transgenic mice. Of the mice singly inactivated for a pocket protein, only the Rb deficient epithelium showed greatly extended E2F1 staining into the suprabasal compartment. Not surprisingly, these results parallel that observed for MCM7 (Fig 4) . EZH2 (enhancer of zeste homologue 2) has been recently identified as a novel target gene activated by HPV-16 E7. EZH2 (i.e., encoded by EZH2) is a component of the PRC2 histone methyltransferase complex, and is also a potential E2F-regulated gene (37) . As for MCM7 and E2F1, staining patterns for EZH2 ( Supplementary Fig. S2) showed that the mice inactivated for both p107 and pRb showed an EZH2 staining Author Manuscript Published OnlineFirst on January 11, 2012; DOI: 10.1158/0008-5472. CAN-11-2833 pattern most similar to that seen in the E7 transgenic mice. These observations are consistent with previous finding that EZH2 induction by HPV-16 E7 is regulated through the inactivation of pocket proteins (38 
Discussion
Our observations demonstrate that the dual inactivation of pRb and p107 nearly fully recapitulates the highly potent oncogenic phenotypes of the HPV16 E7 oncoprotein in head and neck cancer. Indeed, the high incidence as well as high grade of neoplastic disease in the mice deficient for Rb and p107, argues that loss of function of these two genes accounts for E7's ability not only to cause tumors to arise, but also to promote their progression to a fully malignant state. This is a highly significant given that E7 is the driver of HPV-associated head and neck carcinogenesis (13) . It is also remarkable considering that HPV16 E7 has been identified to associate with over 100 other cellular factors, many of which have also been implicated in carcinogenesis. 
dysregulate pocket protein function in the context of the viral life cycle, wherein E7 drives the production of progeny virions in the differentiating epithelia (26) . But it also may explain E7 strong potency in cancer, in that our study demonstrates that the complete inactivation of p107 and pRb can drive head and neck carcinogenesis.
Our study adds to a growing body of research indicating that p107 as well as p130 function as tumor suppressors in mice. Rb Both distinct and redundant functions have been ascribed to the pocket proteins (44) . In our studies, compensatory increases in p130 or p107 were observed in the mice doubly deficient in the other two pocket proteins (Fig 1) . This raised the possibility that increased levels of one pocket protein could suppress tumorigenicity in the head and neck region. For this reason we generated mice deficient for all three pocket proteins by cancer studies on triple-null mice.
In human cancers, mutations in RB are frequently observed, but the same is not true for p107 and p130. This has raised the question whether p107 and p130 are tumor suppressors in the context of human cancers. For most human cancers the answer appears to be no. Yet inactivation of both pRb and the other pocket proteins is a hallmark of HPV-associated cancers, and based upon our findings inactivation of p107 and pRb together both accounts for the potency HPV E7 in causing human cancer, and accounts for the unique biomarker patterns of HPV-associated human cancers. One might ask then, why is it that HPVs cause human cancer in an apparently unique manner. The answer may lie in the recent reports on the mutational profiles of human head and neck cancers. Two groups, using exome analysis, discovered that HPV+ HNSCC have much lower frequencies of mutations in cellular genes compared to HPV-HNSCC, even regardless of the smoking status of the patients with HPV+ HNSCC (45) (46) . This raises the interesting paradox that HR HPVs create a neoplastic environment that is more resistant to the accumulation of mutations than in other neoplasias. For cancers caused primarily by carcinogenic agents this would clearly be a disadvantageous environment.
Another interesting observation made in the above exome analyses was that the Notch pathway is frequently mutated in HNSCC including HPV+ cancers (45) (46) . A recent study has demonstrated that inactivation of pocket proteins lends hepatocellular carcinoma cells sensitive to Notch-mediated tumor suppression (47) . This may provide one explanation for why Notch mutations arise in HPV+ HNSCC. 
